CA2850484C - Compounds for improved viral transduction - Google Patents

Compounds for improved viral transduction Download PDF

Info

Publication number
CA2850484C
CA2850484C CA2850484A CA2850484A CA2850484C CA 2850484 C CA2850484 C CA 2850484C CA 2850484 A CA2850484 A CA 2850484A CA 2850484 A CA2850484 A CA 2850484A CA 2850484 C CA2850484 C CA 2850484C
Authority
CA
Canada
Prior art keywords
cells
cell
hematopoietic stem
progenitor cells
lentivirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2850484A
Other languages
English (en)
French (fr)
Other versions
CA2850484A1 (en
Inventor
Garrett Collins HEFFNER
Abraham Isaac BASSAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bluebird Bio Inc
Original Assignee
Bluebird Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47996444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2850484(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bluebird Bio Inc filed Critical Bluebird Bio Inc
Publication of CA2850484A1 publication Critical patent/CA2850484A1/en
Application granted granted Critical
Publication of CA2850484C publication Critical patent/CA2850484C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2850484A 2011-09-30 2012-09-28 Compounds for improved viral transduction Active CA2850484C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161541736P 2011-09-30 2011-09-30
US61/541,736 2011-09-30
PCT/US2012/057987 WO2013049615A1 (en) 2011-09-30 2012-09-28 Compounds for improved viral transduction

Publications (2)

Publication Number Publication Date
CA2850484A1 CA2850484A1 (en) 2013-04-04
CA2850484C true CA2850484C (en) 2021-01-26

Family

ID=47996444

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2850484A Active CA2850484C (en) 2011-09-30 2012-09-28 Compounds for improved viral transduction

Country Status (19)

Country Link
US (5) US9988644B2 (enExample)
EP (4) EP4095236A1 (enExample)
JP (2) JP6285863B2 (enExample)
KR (1) KR102011532B1 (enExample)
CN (2) CN108220246B (enExample)
AU (1) AU2012315699B2 (enExample)
BR (1) BR112014007782B1 (enExample)
CA (1) CA2850484C (enExample)
CY (1) CY1122654T1 (enExample)
DK (2) DK3269802T3 (enExample)
EA (1) EA032699B1 (enExample)
ES (3) ES2769270T3 (enExample)
IL (2) IL231812B (enExample)
IN (1) IN2014CN02518A (enExample)
MX (2) MX359398B (enExample)
PT (2) PT3269802T (enExample)
SG (2) SG10201602423TA (enExample)
UA (1) UA114796C2 (enExample)
WO (1) WO2013049615A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031907B1 (en) 2008-11-06 2021-01-06 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
CA2850484C (en) 2011-09-30 2021-01-26 Bluebird Bio, Inc. Compounds for improved viral transduction
JP6746313B2 (ja) 2012-08-01 2020-08-26 ユナイテッド セラピューティクス コーポレイション プロスタサイクリン処理された内皮前駆細胞による肺動脈性高血圧症の処置
CN104684561A (zh) * 2012-08-01 2015-06-03 联合治疗公司 利用间充质干细胞的肺动脉高血压的治疗
US20150216903A1 (en) * 2012-08-10 2015-08-06 Bluebird Bio, Inc. Compounds for improved viral transduction
ES2708948T3 (es) 2012-11-27 2019-04-12 Childrens Medical Ct Corp Elementos reguladores distales de bcl11a como dianas para la reinducción de la hemoglobina fetal
KR102466885B1 (ko) 2013-01-09 2022-11-11 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린 및 중간엽 줄기 세포를 사용한 혈관병증의 치료
ES2747951T3 (es) * 2013-10-24 2020-03-12 Ospedale San Raffaele Srl Método
CN106455542A (zh) * 2014-03-26 2017-02-22 布里格姆及妇女医院股份有限公司 用于人造血干/祖细胞的离体扩增的组合物和方法
CN106794260B (zh) 2014-04-25 2021-02-23 儿童医疗中心有限公司 治疗血红蛋白病的组合物和方法
EP3763814A1 (en) 2015-05-08 2021-01-13 The Children's Medical Center Corporation Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
RU2630654C2 (ru) * 2015-07-29 2017-09-11 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Балтийский Федеральный Университет имени Иммануила Канта" (БФУ им. И. Канта) Способ хемогенетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции астроцитов и нейронов
CN105062979A (zh) * 2015-08-21 2015-11-18 昆明理工大学 一种培养戊型肝炎病毒的方法
KR20250134722A (ko) * 2016-02-12 2025-09-11 블루버드 바이오, 인코포레이티드. Vcn 인핸서 조성물 및 이의 사용 방법
CN108883136A (zh) * 2016-02-12 2018-11-23 蓝鸟生物公司 Vcn增强子组合物及其使用方法
AU2017248259A1 (en) * 2016-04-07 2018-10-25 Bluebird Bio, Inc. Chimeric antigen receptor T cell compositions
EP3452170A4 (en) 2016-05-05 2020-04-01 Liquidia Technologies, Inc. TREPROSTINIL IN POWDER FORM FOR TREATING PULMONAL HYPERTENSION
JP7179723B2 (ja) 2016-10-24 2022-11-29 ユナイテッド セラピューティクス コーポレイション トレプロスチニルによるｍｓｃの免疫調節特性の増強
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
SG11201908844YA (en) 2017-03-29 2019-10-30 Bluebird Bio Inc Vectors and compositions for treating hemoglobinopathies
US11788087B2 (en) 2017-05-25 2023-10-17 The Children's Medical Center Corporation BCL11A guide delivery
CA3075755A1 (en) 2017-09-15 2019-03-21 The Medical College Of Wisconsin, Inc. Kidney-targeted epoxyeicosatrienoic acid (eet) analogs
FR3074189A1 (fr) * 2017-11-30 2019-05-31 Assistance Publique - Hopitaux De Paris Methode de generation de greffons de cellules souches hematopoietiques
WO2019196816A1 (zh) * 2018-04-13 2019-10-17 诺未科技（北京）有限公司 丁酸钠的用途及含有丁酸钠的培养体系
CN109207427B (zh) * 2018-09-17 2020-12-08 诺未科技（银川）有限公司 一种将人造血祖细胞转变为造血干细胞的方法
US12239693B2 (en) 2018-04-27 2025-03-04 The Medical College Of Wisconsin, Inc. Use of lentivector-transduced T-Rapa cells for amelioration of lysosomal storage disorders
EP3788070A4 (en) 2018-04-30 2022-03-09 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS OF HEMOGLOBIN PRODUCTION
US12522811B2 (en) 2018-05-01 2026-01-13 The Children's Medical Center Corporation Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9
US12350284B2 (en) 2018-05-02 2025-07-08 The Children's Medical Center Corporation BCL11A microRNAs for treating hemoglobinopathies
US12241079B2 (en) 2018-09-14 2025-03-04 The Children's Hospital Of Philadelphia Compositions and methods for hemoglobin production
US20210386787A1 (en) * 2018-10-12 2021-12-16 Life Technologies Corporation Hematopoietic Stem and Progenitor Cell Expansion System
CN113195003B (zh) 2018-11-30 2024-12-31 国立大学法人京都大学 使用溶液的药物递送系统
JP7853100B2 (ja) 2019-06-05 2026-04-28 オーチャード セラピューティクス（ヨーロッパ）リミテッド 真核細胞を修飾するための組成物及び方法
WO2020264488A1 (en) * 2019-06-28 2020-12-30 The Children's Hospital Of Philadelphia Compositions and methods for treating anemia
US12565643B2 (en) 2019-09-18 2026-03-03 The Medical College Of Wisconsin, Inc. Alpha-galactosidase protein for enzyme replacement therapy (ERT) and methods of use
CA3157966A1 (en) * 2019-10-16 2021-04-22 Orchard Therapeutics (Europe) Limited Compositions and methods for modifying eukaryotic cells
BR112022021862A2 (pt) * 2020-05-27 2023-02-28 Univ Zuerich Aperfeiçoadores de transdução inovadores e usos dos mesmos
JP7887833B2 (ja) * 2020-06-02 2026-07-10 キャタレント ファーマ ソリューションズ リミテッド ライアビリティ カンパニー 遺伝子挿入用の複数のドックを有している細胞株
CN115125270A (zh) * 2021-03-22 2022-09-30 华东师范大学 一种α-珠蛋白过表达载体及其应用
CN113106098B (zh) * 2021-04-21 2022-04-01 贵州医科大学 一种在红系细胞中特异表达人β珠蛋白的重组序列及其应用
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
CN113336833A (zh) * 2021-06-04 2021-09-03 广州伯尼兹生物科技有限公司 一种高效分泌表达猪流行性腹泻病毒s1蛋白的生产方法
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
JP2025530652A (ja) 2022-08-11 2025-09-17 フォンダジオン テレソン イーティーエス 遺伝子治療
EP4602153A1 (en) 2022-10-11 2025-08-20 Fondazione Telethon ETS 3d cell culture methods
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
IT202300011790A1 (it) 2023-06-08 2024-12-08 Fond Telethon Ets Protocolli di manipolazione genica in cellule immunitarie
WO2025056970A1 (en) * 2023-09-12 2025-03-20 Virocell Biologics Ltd Mammalian cell culture additives
IT202300022191A1 (it) 2023-10-24 2025-04-24 Fond Telethon Ets Mezzi e metodi per la modifica genetica di uba1
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
CN118436665A (zh) * 2024-03-22 2024-08-06 浙大城市学院 一类三萜结构及其类似物及在制备抗病毒药物中的应用
EP4640830A1 (en) 2024-04-23 2025-10-29 Fondazione Telethon ETS Means and methods for safe and efficient gene editing in cells
WO2026003694A1 (en) * 2024-06-24 2026-01-02 Csl Behring Llc Methods of enveloped virus transduction

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US568159A (en) 1896-06-26 1896-09-22 Veneering-machine
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
WO1995000657A1 (en) 1993-06-21 1995-01-05 The Uab Research Foundation Anti-sickling hemoglobin
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5869039A (en) 1993-10-15 1999-02-09 Institut National De La Sante Et De La Recherche Medicale X-linked adrenoleukodystrophy gene and corresponding protein
WO1996009385A1 (en) 1994-09-19 1996-03-28 Massachusetts Institute Of Technology Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
KR100793625B1 (ko) * 1995-09-29 2008-01-11 인디아나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 바이러스-매개된 ｄｎａ 전달을 향상시키는 방법에 의해생산된 생존성 세포 집단 및 이를 포함하는 세포 조성물
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
WO1998000542A2 (en) 1996-07-03 1998-01-08 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
WO2000023567A2 (en) 1998-10-16 2000-04-27 Novartis Ag Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
HK1048302A1 (zh) 1999-08-13 2003-03-28 大正制药株式会社 前列腺素衍生物
EP1233986A4 (en) 1999-11-12 2003-01-02 Baxter Biotech Tech Sarl HEMOGLOBIN COMPOSITIONS WITH REDUCED SIDE EFFECTS
CN1272328C (zh) 1999-12-17 2006-08-30 希龙公司 糖元合成酶激酶3的基于吡嗪的抑制剂
ATE327751T1 (de) 2000-01-31 2006-06-15 Pfizer Prod Inc Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
WO2008108741A1 (en) 2007-03-07 2008-09-12 S*Bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
EP1461087A1 (en) 2001-12-06 2004-09-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
GB2399819B (en) 2001-12-24 2005-12-28 Es Cell Int Pte Ltd Method and lentiviral vector for transducing human embryonic stem cells
EP1471818A4 (en) 2002-02-04 2007-03-28 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISEASES USING 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137 , 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 OR 13249 MOLECULES
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
ES2348868T3 (es) 2002-12-13 2010-12-16 Genetix Pharmaceuticals Inc. Vectores retrovirales terapeuticos para terapia genica.
JP4865541B2 (ja) 2003-04-08 2012-02-01 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 化学誘引物質に対する増大させた感受性を有する幹細胞およびそれを産生および使用する方法
DE602004030105D1 (de) * 2003-05-05 2010-12-30 Virxsys Corp Erhöhte transduktion mit abc-transportersubstratenhemmern
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2006001463A1 (ja) 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Ｓ１ｐ受容体結合能を有する化合物およびその用途
WO2006047476A2 (en) 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US20080021078A1 (en) 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
WO2007041511A2 (en) 2005-09-30 2007-04-12 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
US8076315B2 (en) 2005-10-14 2011-12-13 The Board Of Trustees Of The University Of Illinois Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
EP1999255A2 (en) 2006-03-24 2008-12-10 The Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
WO2007124578A1 (en) * 2006-04-27 2007-11-08 Universite De Montreal Assessment and reduction of risk of graft-versus-host disease
WO2007148332A1 (en) 2006-06-22 2007-12-27 Yeda Resaerch And Development Co. Ltd Catecholamine receptor modulation
EP3824885A1 (en) 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
EP3031907B1 (en) * 2008-11-06 2021-01-06 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
EP3533445A1 (en) 2009-03-19 2019-09-04 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
US11459545B2 (en) * 2009-11-15 2022-10-04 Indiana University Research And Technology Corporation Methods to enhance delivery and engraftment of stem cells including the identification of specific prostaglandin E2 receptors
CA2850484C (en) 2011-09-30 2021-01-26 Bluebird Bio, Inc. Compounds for improved viral transduction
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
US20150216903A1 (en) * 2012-08-10 2015-08-06 Bluebird Bio, Inc. Compounds for improved viral transduction
US9943545B2 (en) * 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
ES2747951T3 (es) * 2013-10-24 2020-03-12 Ospedale San Raffaele Srl Método
CN103937743B (zh) * 2014-04-27 2017-12-01 浙江大学 一种利用三维诱导系统获得造血干细胞的方法
JP6980534B2 (ja) * 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
BR112018001232A2 (pt) * 2015-07-21 2018-09-25 The Children's Medical Center Corporation pd-l1 que expressa células-tronco hematopoéticas e usos
KR20250134722A (ko) * 2016-02-12 2025-09-11 블루버드 바이오, 인코포레이티드. Vcn 인핸서 조성물 및 이의 사용 방법
CN108883136A (zh) * 2016-02-12 2018-11-23 蓝鸟生物公司 Vcn增强子组合物及其使用方法
GB201706394D0 (en) * 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
FR3074189A1 (fr) * 2017-11-30 2019-05-31 Assistance Publique - Hopitaux De Paris Methode de generation de greffons de cellules souches hematopoietiques

Also Published As

Publication number Publication date
EP3269802A1 (en) 2018-01-17
UA114796C2 (uk) 2017-08-10
EA032699B1 (ru) 2019-07-31
AU2012315699A1 (en) 2014-05-22
IL281045A (en) 2021-04-29
KR20140069315A (ko) 2014-06-09
JP6285863B2 (ja) 2018-02-28
JP2014530012A (ja) 2014-11-17
EA201490627A1 (ru) 2014-11-28
US10907177B2 (en) 2021-02-02
MX2014003923A (es) 2014-05-07
MX359398B (es) 2018-09-27
WO2013049615A1 (en) 2013-04-04
BR112014007782B1 (pt) 2021-06-01
EP2760994B2 (en) 2021-09-15
EP3656848B1 (en) 2022-03-16
BR112014007782A2 (pt) 2017-04-11
ES2632444T3 (es) 2017-09-13
IL231812B (en) 2021-03-25
IL231812A0 (en) 2014-05-28
US20180363004A1 (en) 2018-12-20
JP6745826B2 (ja) 2020-08-26
DK3269802T3 (da) 2020-02-03
US20210171980A1 (en) 2021-06-10
US11834668B2 (en) 2023-12-05
EP2760994A1 (en) 2014-08-06
US20200048657A1 (en) 2020-02-13
PT3269802T (pt) 2020-01-28
EP4095236A1 (en) 2022-11-30
PT2760994T (pt) 2017-08-24
CN108220246A (zh) 2018-06-29
IL281045B (en) 2022-02-01
EP2760994B1 (en) 2017-05-31
NZ623341A (en) 2016-04-29
CN108220246B (zh) 2022-07-12
KR102011532B1 (ko) 2019-08-16
SG10201602423TA (en) 2016-05-30
ES2769270T3 (es) 2020-06-25
US10501759B2 (en) 2019-12-10
ES2632444T5 (es) 2022-03-02
ES2913633T3 (es) 2022-06-03
SG11201401077PA (en) 2014-04-28
AU2012315699B2 (en) 2017-08-17
DK2760994T4 (da) 2021-10-11
US9988644B2 (en) 2018-06-05
CY1122654T1 (el) 2021-03-12
EP3656848A1 (en) 2020-05-27
DK2760994T3 (en) 2017-08-07
CN103958667A (zh) 2014-07-30
US20240229070A1 (en) 2024-07-11
MX2018011791A (es) 2021-12-08
US20140234278A1 (en) 2014-08-21
EP2760994B8 (en) 2017-07-26
IN2014CN02518A (enExample) 2015-07-31
EP3269802B1 (en) 2019-10-23
CA2850484A1 (en) 2013-04-04
JP2018099124A (ja) 2018-06-28
EP2760994A4 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
US11834668B2 (en) Compounds for improved viral transduction
AU2017217813B2 (en) VCN enhancer compositions and methods of using the same
US20150216903A1 (en) Compounds for improved viral transduction
EP3413896B1 (en) Vcn enhancer compositions and methods of using the same
WO2014015318A1 (en) Soluble compounds for improved gene therapy methods
NZ623341B2 (en) Compounds for improved viral transduction
HK40002130B (en) Vcn enhancer compositions and methods of using the same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170926

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250328